Definition of SU011248 - NCI Dictionary of Cancer Terms

Page Options

	Quick Links


	Director's Corner Updates from the Director Dictionary of Cancer Terms Cancer-related terms NCI Drug Dictionary Definitions, names, and links Funding Opportunities Research and training NCI Publications Order/download free booklets Advisory Boards and Groups Information, meetings, reports Science Serving People Learn more about NCI Español Información en español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

Quit Smoking Today

	NCI Highlights


	Report to Nation Finds Declines in Cancer Incidence, Death Rates High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E The Nation's Investment in Cancer Research FY 2009 Past Highlights

Search for

Starts with

Contains

In English En español

SU011248

A drug used to treat gastrointestinal stromal tumors (GIST) that have not responded to treatment with imatinib mesylate (Gleevec). SU011248 is also used to treat advanced kidney cancer and is being studied in the treatment of other types of cancer. It is a type of tyrosine kinase inhibitor, a type of vascular endothelial growth factor (VEGF) receptor inhibitor, and a type of angiogenesis inhibitor. Also called SU11248, sunitinib, sunitinib malate, and Sutent.

Previous Definitions:	strontium ranelate, strontium-89, study agent, Sturge-Weber syndrome, SU006668
Next Definitions:	SU101, SU11248, SU5416, SU6668, subcutaneous